| |
| |
|
| Insider
Information: |
Scheibler Lukas |
| Relationship: |
Chief Research Officer |
| City: |
Seattle |
| State: |
WA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
68,299 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$2,821,432 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
68,299 |
|
|
| Total
Value |
$2,821,432 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
1
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
1
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-1.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -1.8%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Apellis Pharmaceuticals Inc |
APLS |
Chief Research Officer |
2023-12-01 |
68,299 |
2018-05-24 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
34 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 2
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| APLS |
Apellis Pharmaceuticals I... |
See Remarks |
• – – |
2018-05-24 |
4 |
B |
$20.37 |
$59,786 |
D/D |
2,935 |
2,935 |
2.74 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
See Remarks |
• – – |
2020-02-10 |
4 |
A |
$0.00 |
$0 |
D/D |
9,375 |
12,310 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
CHIEF INNOVATION OFFICER |
• • – |
2020-12-08 |
4 |
OE |
$26.73 |
$199,994 |
D/D |
7,482 |
20,595 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
CHIEF INNOVATION OFFICER |
• • – |
2021-01-28 |
4 |
A |
$0.00 |
$0 |
D/D |
9,375 |
29,970 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
CHIEF INNOVATION OFFICER |
• • – |
2021-02-10 |
4 |
D |
$47.72 |
$32,450 |
D/D |
(680) |
29,290 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
CHIEF INNOVATION OFFICER |
• • – |
2021-06-10 |
4 |
AS |
$60.00 |
$205,020 |
D/D |
(3,417) |
26,651 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
CHIEF INNOVATION OFFICER |
• • – |
2022-01-21 |
4 |
OE |
$26.73 |
$80,751 |
D/D |
3,021 |
29,681 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
CHIEF INNOVATION OFFICER |
• • – |
2022-01-21 |
4 |
A |
$0.00 |
$0 |
D/D |
26,051 |
55,732 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
CHIEF INNOVATION OFFICER |
• • – |
2022-01-28 |
4 |
D |
$38.59 |
$24,775 |
D/D |
(642) |
55,090 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
CHIEF INNOVATION OFFICER |
• • – |
2022-01-31 |
4 |
AS |
$38.47 |
$47,434 |
D/D |
(1,233) |
53,857 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
CHIEF INNOVATION OFFICER |
• • – |
2022-02-08 |
4 |
OE |
$13.85 |
$138,500 |
D/D |
10,000 |
63,857 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
CHIEF INNOVATION OFFICER |
• • – |
2022-02-08 |
4 |
AS |
$45.00 |
$450,000 |
D/D |
(10,000) |
53,857 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
CHIEF INNOVATION OFFICER |
• • – |
2022-02-10 |
4 |
AS |
$50.00 |
$500,000 |
D/D |
(10,000) |
53,179 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
CHIEF INNOVATION OFFICER |
• • – |
2022-02-10 |
4 |
OE |
$13.85 |
$138,500 |
D/D |
10,000 |
63,179 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
CHIEF INNOVATION OFFICER |
• • – |
2022-02-10 |
4 |
D |
$47.12 |
$31,947 |
D/D |
(678) |
53,179 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
CHIEF INNOVATION OFFICER |
• • – |
2022-02-11 |
4 |
AS |
$46.80 |
$77,969 |
D/D |
(1,666) |
51,513 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
CHIEF INNOVATION OFFICER |
• • – |
2022-02-14 |
4 |
OE |
$26.73 |
$19,246 |
D/D |
720 |
52,233 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
CHIEF INNOVATION OFFICER |
• • – |
2022-04-01 |
4 |
OE |
$13.85 |
$159,220 |
D/D |
11,496 |
63,729 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
CHIEF INNOVATION OFFICER |
• • – |
2022-04-01 |
4 |
AS |
$55.05 |
$632,855 |
D/D |
(11,496) |
52,233 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
CHIEF INNOVATION OFFICER |
• • – |
2022-04-04 |
4 |
AS |
$55.84 |
$199,589 |
D/D |
(3,504) |
52,233 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
CHIEF INNOVATION OFFICER |
• • – |
2022-04-04 |
4 |
OE |
$13.85 |
$48,530 |
D/D |
3,504 |
55,737 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
CHIEF INNOVATION OFFICER |
• • – |
2022-04-05 |
4 |
OE |
$13.85 |
$8,435 |
D/D |
609 |
52,842 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
CHIEF INNOVATION OFFICER |
• • – |
2022-04-05 |
4 |
AS |
$60.09 |
$36,593 |
D/D |
(609) |
52,233 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
CHIEF INNOVATION OFFICER |
• • – |
2022-04-21 |
4 |
AS |
$0.00 |
$0 |
D/D |
(1,875) |
50,358 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
CHIEF INNOVATION OFFICER |
• • – |
2022-05-27 |
4 |
AS |
$43.00 |
$430,000 |
D/D |
(10,000) |
40,358 |
0 |
% |
|
34 Records found
|
|
Page 1 of 2 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
